Brokerages expect Tabula Rasa HealthCare Inc (NASDAQ:TRHC) to announce earnings per share of $0.06 for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Tabula Rasa HealthCare’s earnings. The highest EPS estimate is $0.10 and the lowest is $0.02. Tabula Rasa HealthCare reported earnings of $0.22 per share in the same quarter last year, which would suggest a negative year over year growth rate of 72.7%. The firm is scheduled to report its next quarterly earnings results on Thursday, November 5th.
On average, analysts expect that Tabula Rasa HealthCare will report full year earnings of $0.21 per share for the current year, with EPS estimates ranging from $0.02 to $0.30. For the next financial year, analysts anticipate that the business will post earnings of $0.62 per share, with EPS estimates ranging from $0.23 to $0.74. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that cover Tabula Rasa HealthCare.
Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.29. Tabula Rasa HealthCare had a negative net margin of 14.70% and a negative return on equity of 7.37%. The firm had revenue of $76.80 million during the quarter, compared to analysts’ expectations of $78.12 million. During the same period in the prior year, the company posted $0.35 EPS. The company’s revenue was up .7% on a year-over-year basis.
A number of research firms have recently commented on TRHC. Piper Sandler reduced their price objective on shares of Tabula Rasa HealthCare from $68.00 to $59.00 and set an “overweight” rating on the stock in a research note on Thursday, August 6th. SunTrust Banks began coverage on shares of Tabula Rasa HealthCare in a research note on Thursday, July 2nd. They issued a “buy” rating and a $72.00 price objective on the stock. Zacks Investment Research raised shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research note on Thursday, August 6th. Cantor Fitzgerald reduced their price objective on shares of Tabula Rasa HealthCare from $85.00 to $83.00 and set an “overweight” rating on the stock in a research note on Thursday, June 25th. Finally, ValuEngine raised shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research note on Thursday, July 30th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $64.45.
In other Tabula Rasa HealthCare news, CEO Calvin H. Knowlton sold 16,000 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $48.62, for a total value of $777,920.00. Following the transaction, the chief executive officer now directly owns 764,881 shares of the company’s stock, valued at $37,188,514.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, President Orsula V. Knowlton sold 8,000 shares of the firm’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $58.81, for a total transaction of $470,480.00. Following the completion of the transaction, the president now directly owns 741,756 shares in the company, valued at $43,622,670.36. The disclosure for this sale can be found here. Insiders sold 61,140 shares of company stock worth $3,215,108 over the last ninety days. Insiders own 11.60% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Nuveen Asset Management LLC boosted its position in Tabula Rasa HealthCare by 13.0% during the first quarter. Nuveen Asset Management LLC now owns 77,234 shares of the company’s stock worth $4,039,000 after purchasing an additional 8,877 shares during the period. Legal & General Group Plc boosted its position in Tabula Rasa HealthCare by 6.7% during the first quarter. Legal & General Group Plc now owns 56,388 shares of the company’s stock worth $2,930,000 after purchasing an additional 3,524 shares during the period. BNP Paribas Arbitrage SA boosted its position in Tabula Rasa HealthCare by 66.6% during the first quarter. BNP Paribas Arbitrage SA now owns 8,289 shares of the company’s stock worth $433,000 after purchasing an additional 3,313 shares during the period. Balyasny Asset Management LLC bought a new position in shares of Tabula Rasa HealthCare in the first quarter valued at approximately $520,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Tabula Rasa HealthCare by 48.4% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,891 shares of the company’s stock valued at $517,000 after acquiring an additional 3,226 shares during the period.
Shares of NASDAQ:TRHC traded up $0.07 during trading on Tuesday, reaching $50.08. The stock had a trading volume of 291,018 shares, compared to its average volume of 304,963. The firm’s fifty day moving average is $52.40 and its 200 day moving average is $55.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 2.31 and a current ratio of 2.41. Tabula Rasa HealthCare has a 52 week low of $33.04 and a 52 week high of $69.72. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -24.31 and a beta of 0.99.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
Featured Article: What is the definition of market timing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.